A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 +Dabrafenib Under Adaptable Dosing Schedules in Patients With Advanced Solid Tumors That Are Metastatic or Cannot be Removed by Surgery

Trial Profile

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 +Dabrafenib Under Adaptable Dosing Schedules in Patients With Advanced Solid Tumors That Are Metastatic or Cannot be Removed by Surgery

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs AZD 5363 (Primary) ; Dabrafenib
  • Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top